Medincell Sa Stock Annual Yield
| MDCLF Stock | USD 6.98 0.00 0.00% |
Fundamental analysis of MedinCell allows traders to better anticipate movements in MedinCell's stock price by examining its financial health and performance throughout various phases of its business cycle.
MedinCell |
MedinCell SA Company Annual Yield Analysis
MedinCell's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, MedinCell SA has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.